| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
Anlotinib plus penpulimab versus sorafenib in the first-line treatment of unresectable hepatocellular carcinoma (APOLLO): a randomised, controlled, phase 3 trial
|
Zhou, Jian
|
|
|
26 |
6 |
p. 719-731
|
artikel
|
| 2 |
Association between risk-reducing surgeries and survival in young BRCA carriers with breast cancer: an international cohort study
|
Blondeaux, Eva
|
|
|
26 |
6 |
p. 759-770
|
artikel
|
| 3 |
Causes of subsequent neoplasms after childhood cancer
|
Kuehni, Claudia E
|
|
|
26 |
6 |
p. 673-675
|
artikel
|
| 4 |
Combination of encorafenib and binimetinib followed by ipilimumab and nivolumab versus ipilimumab and nivolumab in patients with advanced melanoma with BRAF V600E or BRAF V600K mutations (EBIN): an international, open-label, randomised, controlled, phase 2 study
|
Robert, Caroline
|
|
|
26 |
6 |
p. 781-794
|
artikel
|
| 5 |
Contributions of cancer treatment and genetic predisposition to risk of subsequent neoplasms in long-term survivors of childhood cancer: a report from the St Jude Lifetime Cohort and the Childhood Cancer Survivor Study
|
Neupane, Achal
|
|
|
26 |
6 |
p. 806-816
|
artikel
|
| 6 |
Correction to Lancet Oncol 2025; 26: 559–70
|
|
|
|
26 |
6 |
p. e298
|
artikel
|
| 7 |
Docetaxel as part of first-line chemotherapy for gastric cancer
|
Kelsen, David
|
|
|
26 |
6 |
p. 669-671
|
artikel
|
| 8 |
Enfortumab vedotin plus pembrolizumab versus chemotherapy in patients with previously untreated locally advanced or metastatic urothelial cancer (EV-302): patient-reported outcomes from an open-label, randomised, controlled, phase 3 study
|
Gupta, Shilpa
|
|
|
26 |
6 |
p. 795-805
|
artikel
|
| 9 |
ESTRO 2025
|
Collingridge, David
|
|
|
26 |
6 |
p. 686
|
artikel
|
| 10 |
European cancer workforce: under pressure
|
Oldenmenger, Wendy H
|
|
|
26 |
6 |
p. 678-680
|
artikel
|
| 11 |
Health insurance system in Japan faces risk of politicisation
|
Das, Manjulika
|
|
|
26 |
6 |
p. e299
|
artikel
|
| 12 |
ICGC-ARGO precision medicine: an update on immunotherapy response in metastatic head and neck squamous cell carcinoma
|
Nocini, Riccardo
|
|
|
26 |
6 |
p. 691-692
|
artikel
|
| 13 |
Immunotherapy plus tyrosine-kinase inhibitors in hepatocellular carcinoma
|
Cammarota, Antonella
|
|
|
26 |
6 |
p. 667-669
|
artikel
|
| 14 |
Impact of suboptimal cancer care in the Commonwealth: a scoping review and call to action
|
Thibodeau, Stephane
|
|
|
26 |
6 |
p. e311-e319
|
artikel
|
| 15 |
Long-term health outcomes of bilateral salpingo-oophorectomy in BRCA1 and BRCA2 pathogenic variant carriers with personal history of breast cancer: a retrospective cohort study using linked electronic health records
|
Hassan, Hend
|
|
|
26 |
6 |
p. 771-780
|
artikel
|
| 16 |
Misunderstood trial design: randomisation compels comparison
|
Sherry, Alexander D
|
|
|
26 |
6 |
p. e297
|
artikel
|
| 17 |
National cancer control plans in Latin America and the Caribbean: challenges and future directions
|
Villarreal-Garza, Cynthia
|
|
|
26 |
6 |
p. e320-e330
|
artikel
|
| 18 |
Navigating the complexity: reflections on the development of perioperative cancer treatments
|
Zosso-Pavic, Matea
|
|
|
26 |
6 |
p. 675-678
|
artikel
|
| 19 |
New chemotherapy database to monitor ovarian cancer treatment in New Zealand
|
Das, Manjulika
|
|
|
26 |
6 |
p. 683
|
artikel
|
| 20 |
Nutrition in head and neck cancer care: a roadmap and call for research
|
Chen, Xin
|
|
|
26 |
6 |
p. e300-e310
|
artikel
|
| 21 |
Optimism in the face of adversity
|
Mellor, Daniel
|
|
|
26 |
6 |
p. 694
|
artikel
|
| 22 |
Primary granulocytic sarcoma of the breast
|
Le, Yali
|
|
|
26 |
6 |
p. e331
|
artikel
|
| 23 |
Promoting sustainability in oncology care: an international call to legalise the redispensing of unused oral anticancer drugs with quality assurance protocols
|
Smale, Elisabeth
|
|
|
26 |
6 |
p. 680-681
|
artikel
|
| 24 |
Proposed tariffs on pharmaceuticals cause concerns about increased drug prices and drug shortages in the USA
|
Devi, Sharmila
|
|
|
26 |
6 |
p. 682
|
artikel
|
| 25 |
Risk-reducing surgery in BRCA carriers: do we need more evidence?
|
Sacchini, Virgilio
|
|
|
26 |
6 |
p. 671-673
|
artikel
|
| 26 |
Salvage metastasis-directed therapy versus elective nodal radiotherapy for oligorecurrent nodal prostate cancer metastases (PEACE V–STORM): a phase 2, open-label, randomised controlled trial
|
Ost, Piet
|
|
|
26 |
6 |
p. 695-706
|
artikel
|
| 27 |
Standard versus reduced-dose chemoradiotherapy in anal cancer (PLATO-ACT4): short-term results of a phase 2 randomised controlled trial
|
Gilbert, Alexandra
|
|
|
26 |
6 |
p. 707-718
|
artikel
|
| 28 |
Targeted treatment of oligorecurrent prostate cancer?
|
Falkenbach, Fabian
|
|
|
26 |
6 |
p. 666-667
|
artikel
|
| 29 |
TFOX versus FOLFOX in first-line treatment of patients with advanced HER2-negative gastric or gastro-oesophageal junction adenocarcinoma (PRODIGE 51- FFCD-GASTFOX): an open-label, multicentre, randomised, phase 3 trial
|
Zaanan, Aziz
|
|
|
26 |
6 |
p. 732-744
|
artikel
|
| 30 |
The BREAKING-ICE App: an interactive journey into informative censoring
|
Olivier, Timothée
|
|
|
26 |
6 |
p. 693
|
artikel
|
| 31 |
UK cancer researchers reaping the rewards of return to EU Horizon programme funding
|
Kirby, Tony
|
|
|
26 |
6 |
p. 685
|
artikel
|
| 32 |
UK urged to support cancer research collaboration with EU
|
Devi, Sharmila
|
|
|
26 |
6 |
p. 684
|
artikel
|
| 33 |
US Clean Air in the firing line
|
The Lancet Oncology,
|
|
|
26 |
6 |
p. 663
|
artikel
|
| 34 |
Use of patient-reported outcomes to inform symptom and functional outcomes in cancer drug regulatory decisions: challenges and future directions
|
Pignatti, Francesco
|
|
|
26 |
6 |
p. 664-666
|
artikel
|
| 35 |
Using patient-reported outcomes and health-related quality of life data in regulatory decisions on cancer treatment: highlights from an EMA-EORTC workshop
|
Pe, Madeline
|
|
|
26 |
6 |
p. 687-690
|
artikel
|
| 36 |
Young-PEARL trial: paradoxical results of overall survival
|
Yin, Wenjin
|
|
|
26 |
6 |
p. e295
|
artikel
|
| 37 |
Young-PEARL trial: paradoxical results of overall survival – Authors' reply
|
Ahn, Hee Kyung
|
|
|
26 |
6 |
p. e296
|
artikel
|
| 38 |
Zanidatamab plus palbociclib and fulvestrant in previously treated patients with hormone receptor-positive, HER2-positive metastatic breast cancer: primary results from a two-part, multicentre, single-arm, phase 2a study
|
Escrivá-de-Romani, Santiago
|
|
|
26 |
6 |
p. 745-758
|
artikel
|
Tijdschrift beschrijving